Somite.ai Announces Strategic Investment from AMD Ventures to Accelerate Foundation Models for Cell Therapy

BOSTON, Aug. 20, 2025 /PRNewswire/ -- Somite.ai, a company pioneering foundation models for human stem cells, today announced a strategic investment from AMD Ventures, following Somite's $47M Series A closing led by Khosla Ventures in May. The collaboration pairs Somite's capsule-based data generation platform with industry-leading AMD Instinct™ GPUs, significantly boosting compute power to accelerate training of Somite's foundation models.

Somite is transforming cell therapy by building large-scale foundation models to rapidly accelerate the development of novel cell therapies, significantly compressing timelines and potentially benefiting millions of patients. The company's proprietary capsule technology generates differentiation data at approximately one-thousandth the cost of traditional methods, unlocking unprecedented scale and precision for training powerful predictive models.

"We are on the cusp of a true breakthrough in data generation for cell-state transitions. Our capsule-based platform provides dense, causal datasets essential for training transformative foundation models. AMD is uniquely positioned to help us deliver on our promise," said Dr. Micha Breakstone, Co-Founder and CEO of Somite.ai.

"Biology is experiencing a computational revolution similar to language and vision. Somite is clearly leading the way, and AMD Instinct GPUs are built for the demands of their ambitious models," said Sagi Paz, Head of AMD Ventures. "We are excited to collaborate with a company converting cutting-edge compute capabilities into meaningful therapies."

The collaboration will explore optimization of software tools for biological data and joint efforts to develop solutions tailored for next-generation foundation models.

About Somite.ai

Somite.ai is developing AI foundation models for human stem cells to drive novel cell therapies at scale. Somite takes a full-stack approach—generating data at 1,000x lower cost, training large-scale models with unmatched predictive power, and using these models to discover, refine, and optimize high-impact applications in cell therapy. The founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT (pioneered foundational research on scaling laws), and three National Academy of Science members. Based in Boston and launching operations in January 2024, Somite has raised approximately $60M to date.

Media Contacts
[email protected]

SOURCE Somite Therapeutics